Blake is the cofounder and CEO of Transcend Therapeutics, a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric diseases. Our mission is to develop new drugs for the millions of people for whom current psychiatric medicines have not worked. Transcend’s lead product candidate, TNSD-201 (methylone) — a rapid-acting neuroplastogen — recently demonstrated rapid, robust therapeutic effects in patients with post-traumatic stress disorder (PTSD), with remission achieved by the majority of participants (61.5%) at end of study. Transcend has raised approximately $42M to date.Blake was named to Forbes' "30 under 30" and has lectured at University of Pennsylvania and Brown University.
Listed skills include Entrepreneurship, Public Speaking, Start Ups, Team Leadership, and 12 others.